{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:44:20Z","timestamp":1790703860117,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Projects Foundation of Guangzhou city","award":["202201020095"],"award-info":[{"award-number":["202201020095"]}]},{"name":"Beijing Jingjian Pathology Development Foundation","award":["JJDYSG2023-018"],"award-info":[{"award-number":["JJDYSG2023-018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12980-6","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:01:58Z","timestamp":1727686918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhongtang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"6","key":"12980_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12980_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12980_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10549-019-05295-9","volume":"177","author":"M Krystel-Whittemore","year":"2019","unstructured":"Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, et al. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;177(1):61\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"12980_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer CE Jr., Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, et al. NSABP B-47\/NRG oncology phase III Randomized Trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast Cancer negative for HER2 by FISH and with IHC 1\u2009+\u2009or 2. J Clin Oncol. 2020;38(5):444\u201353.","journal-title":"J Clin Oncol"},{"issue":"5","key":"12980_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.17219\/acem\/27923","volume":"24","author":"M Wesola","year":"2015","unstructured":"Wesola M, Jelen M. A comparison of IHC and FISH cytogenetic methods in the evaluation of HER2 status in breast Cancer. Adv Clin Exp Med. 2015;24(5):899\u2013903.","journal-title":"Adv Clin Exp Med"},{"key":"12980_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-3444-7_5","volume":"1406","author":"HC Hwang","year":"2016","unstructured":"Hwang HC, Gown AM. Evaluation of human epidermal growth factor receptor 2 (HER2) gene status in human breast Cancer formalin-fixed paraffin-embedded (FFPE) tissue specimens by fluorescence in situ hybridization (FISH). Methods Mol Biol. 2016;1406:61\u201370.","journal-title":"Methods Mol Biol"},{"issue":"20","key":"12980_CR7","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"12980_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351.","journal-title":"N Engl J Med"},{"issue":"31","key":"12980_CR9","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"3","key":"12980_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the antibody-drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173\u201385.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"12980_CR11","doi-asserted-by":"publisher","first-page":"111682","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, et al. Novel HER2-Targeting antibody-drug conjugates of Trastuzumab Beyond T-DM1 in breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.","journal-title":"Eur J Med Chem"},{"key":"12980_CR12","doi-asserted-by":"crossref","unstructured":"Diaz-Rodriguez E, Gandullo-Sanchez L, Ocana A, Pandiella A. Novel ADCs and strategies to overcome resistance to Anti-HER2 ADCs. Cancers (Basel) 2021, 14(1).","DOI":"10.3390\/cancers14010154"},{"issue":"1","key":"12980_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","volume":"23","author":"E Ferraro","year":"2021","unstructured":"Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021;23(1):84.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"12980_CR14","first-page":"1288","volume":"44","author":"International Medical Society CA-CA, Breast Cancer Group BoOCMDA","year":"2022","unstructured":"International Medical Society CA-CA, Breast Cancer Group BoOCMDA. [Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)]. Zhonghua Zhong Liu Za Zhi. 2022;44(12):1288\u201395.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"4","key":"12980_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, et al. Examination of low ERBB2 protein expression in breast Cancer tissue. JAMA Oncol. 2022;8(4):1\u20134.","journal-title":"JAMA Oncol"},{"issue":"4","key":"12980_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1309\/AJCP4A7KTAYHZSOE","volume":"140","author":"K Lambein","year":"2013","unstructured":"Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, Matthys B, Praet M, Denys H, Libbrecht L. Distinguishing score 0 from score 1\u2009+\u2009in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol. 2013;140(4):561\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"12980_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/his.13333","volume":"72","author":"T Qaiser","year":"2018","unstructured":"Qaiser T, Mukherjee A, Reddy Pb C, Munugoti SD, Tallam V, Pitkaaho T, Lehtimaki T, Naughton T, Berseth M, Pedraza A, et al. HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues. Histopathology. 2018;72(2):227\u201338.","journal-title":"Histopathology"},{"issue":"1","key":"12980_CR18","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1038\/s41467-023-40218-9","volume":"14","author":"CD Gatenbee","year":"2023","unstructured":"Gatenbee CD, Baker AM, Prabhakaran S, Swinyard O, Slebos RJC, Mandal G, Mulholland E, Andor N, Marusyk A, Leedham S, et al. Virtual alignment of pathology image series for multi-gigapixel whole slide images. Nat Commun. 2023;14(1):4502.","journal-title":"Nat Commun"},{"key":"12980_CR19","doi-asserted-by":"crossref","unstructured":"Li Y, Zhang X, Chen DJI. CSRNet: Dilated Convolutional Neural Networks for Understanding the Highly Congested Scenes. 2018.","DOI":"10.1109\/CVPR.2018.00120"},{"issue":"10","key":"12980_CR20","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1109\/TPAMI.2020.2983686","volume":"43","author":"J Wang","year":"2021","unstructured":"Wang J, Sun K, Cheng T, Jiang B, Deng C, Zhao Y, Liu D, Mu Y, Tan M, Wang X, et al. Deep high-resolution representation learning for visual recognition. IEEE Trans Pattern Anal Mach Intell. 2021;43(10):3349\u201364.","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"issue":"9","key":"12980_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ncponc1179","volume":"5","author":"A Prat","year":"2008","unstructured":"Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008;5(9):531\u201342.","journal-title":"Nat Clin Pract Oncol"},{"issue":"11","key":"12980_CR22","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512\u201322.","journal-title":"Lancet Oncol"},{"issue":"11","key":"12980_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/modpathol.3880440","volume":"14","author":"TA Thomson","year":"2001","unstructured":"Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL. HER-2\/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14(11):1079\u201386.","journal-title":"Mod Pathol"},{"issue":"17","key":"12980_CR24","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in patients with HER2-Low-expressing advanced breast Cancer: results from a phase ib study. J Clin Oncol. 2020;38(17):1887\u201396.","journal-title":"J Clin Oncol"},{"issue":"3","key":"12980_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00428-021-03154-x","volume":"479","author":"M Yue","year":"2021","unstructured":"Yue M, Zhang J, Wang X, Yan K, Cai L, Tian K, Niu S, Han X, Yu Y, Huang J, et al. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study. Virchows Arch. 2021;479(3):443\u20139.","journal-title":"Virchows Arch"},{"issue":"2","key":"12980_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10549-015-3475-3","volume":"152","author":"H Holten-Rossing","year":"2015","unstructured":"Holten-Rossing H, Moller Talman ML, Kristensson M, Vainer B. Optimizing HER2 assessment in breast cancer: application of automated image analysis. Breast Cancer Res Treat. 2015;152(2):367\u201375.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"12980_CR27","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.modpat.2022.100054","volume":"36","author":"S Wu","year":"2023","unstructured":"Wu S, Yue M, Zhang J, Li X, Li Z, Zhang H, Wang X, Han X, Cai L, Shang J, et al. The role of Artificial Intelligence in Accurate Interpretation of HER2 immunohistochemical scores 0 and 1\u2009+\u2009in breast Cancer. Mod Pathol. 2023;36(3):100054.","journal-title":"Mod Pathol"},{"issue":"3","key":"12980_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/his.14140","volume":"77","author":"AI Hida","year":"2020","unstructured":"Hida AI, Omanovic D, Pedersen L, Oshiro Y, Ogura T, Nomura T, Kurebayashi J, Kanomata N, Moriya T. Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging. Histopathology. 2020;77(3):471\u201380.","journal-title":"Histopathology"},{"issue":"3","key":"12980_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41379-021-00904-9","volume":"35","author":"J Wu","year":"2022","unstructured":"Wu J, Liu C, Liu X, Sun W, Li L, Gao N, Zhang Y, Yang X, Zhang J, Wang H, et al. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Mod Pathol. 2022;35(3):403\u201311.","journal-title":"Mod Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12980-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:03:32Z","timestamp":1727687012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12980-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12980"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12980-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethics Committee and the Institutional Review Committee of the Third Affiliated Hospital of Guangzhou Medical University (No. 2024129) and was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1204"}}